Envoy Medical vs Nexalin Technology
Nexalin Technology reported revenue of $0 million in fiscal 2025, 1.5 times Envoy Medical's $0 million in fiscal 2025. Envoy Medical's revenue grew 7.1% in its latest year, and Nexalin Technology's grew 78.8%. Envoy Medical had an operating margin of -9240.7%, against -2781.7% at Nexalin Technology.
Side by side
| Envoy Medical | Nexalin Technology | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $0M |
| Revenue growth | 7.1% | 78.8% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | −262.7% | 79.7% |
| Operating margin | −9,240.7% | −2,781.7% |
| Net margin | −9,857.3% | −2,725.8% |
| Free cash flow | −$18M | — |
| Free cash flow margin | −7,626.6% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $2M | $0M |
| Change in diluted share count | 23.8% | 77.9% |
| Last close | $6.70 | $1.39 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Envoy MedicalNexalin Technology
Operating margin
Percent of revenue
Envoy MedicalNexalin Technology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Envoy MedicalNexalin Technology
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Envoy Medical and Nexalin Technology pages.